title: Dendritic cell-targeted vaccines--hope or hype?
abstract: The development of an effective vaccine that elicits a strong and durable T cell response against intracellular pathogens and cancer is a challenge. One strategy to enhance the effectiveness of vaccination is by targeting dendritic cells (DCs). In this Opinion article, we discuss existing DC-targeting approaches that induce adaptive immunity. We highlight the crucial issues that need to be addressed to move the field forward and discuss whether targeting DCs could be better than current vaccine approaches.
authors.affiliation: Institute of Molecular Medicine, University of Bonn, 53105 Bonn, Germany.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Kastenmüller
authors.affiliation: Institute of Experimental Immunology and the Department of General Practice and Family Medicine, University of Bonn, 53105 Bonn, Germany.
authors.forename: Kathrin
authors.initials: K
authors.lastname: Kastenmüller
authors.affiliation: Institute of Experimental Immunology, University of Bonn, 53105 Bonn, Germany.
authors.forename: Christian
authors.initials: C
authors.lastname: Kurts
authors.affiliation: Cellular Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892-3005, USA.
authors.forename: Robert A
authors.initials: RA
authors.lastname: Seder
mesh_terms: D056704:Adaptive Immunity / Q000276:immunology; D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D051379:Mice; D018448:Models, Immunological; D009369:Neoplasms / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014611:Vaccination
chemical_list: D019496:Cancer Vaccines